AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
UBS Downgrades Thermo Fisher Scientific to Neutral on Life Sciences R&D Headwinds
ByAinvest
Thursday, Jul 10, 2025 3:14 am ET1min read
UBS downgraded Thermo Fisher Scientific to neutral from buy, citing headwinds in life sciences R&D spend. The bank cut its price target to $460 from $500, representing an 8% upside from the July 10 close.
UBS has downgraded Thermo Fisher Scientific (NYSE:TMO) to neutral from buy, citing headwinds in life sciences R&D spend. The bank has cut its price target to $460 from $500, representing an 8% upside from the July 10 close [1].The downgrade comes as UBS adjusts its outlook on the company's stock performance, reflecting a series of challenges that could negatively impact life sciences R&D spend. The bank's new price target of $460 is a significant reduction from the previous estimate of $500 [2].
Analysts have provided a range of price targets for TMO, with the average target price at $551.12, implying an average upside of 29.32% from the current price of $426.17. Despite the UBS downgrade, the consensus recommendation from brokerage firms remains "Outperform" [2].
In its Q1 2025 earnings report, Thermo Fisher Scientific reported strong financial performance, with revenue of $10.36 billion and adjusted EPS growth of 1% to $5.15 per share. The company also launched several innovative products and executed its capital deployment strategy, including a $4.1 billion acquisition agreement and $2 billion in share repurchases [2].
However, the company faced revenue declines in the Academic and Government segment due to macroeconomic conditions in the US and China. Additionally, the company anticipates a $400 million revenue headwind due to US-China tariffs and a $500 million reduction in revenue expectations due to policy changes impacting US Academic and Government customers and clinical trials related to vaccines [2].
UBS's downgrade reflects the company's updated guidance to reflect macroeconomic uncertainties, which are expected to impact revenue and adjusted EPS. The bank's new price target of $460 is a significant reduction from the previous estimate of $500, highlighting the potential challenges ahead for Thermo Fisher Scientific [1].
References:
[1] https://seekingalpha.com/news/4466262-thermo-fisher-scientific-downgraded-ubs-life-sciences-r-and-d-headwinds
[2] https://www.gurufocus.com/news/2965053/thermo-fisher-tmo-receives-downgrade-from-ubs-with-reduced-price-target-tmo-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet